{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:21:49Z","timestamp":1770751309732,"version":"3.50.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG13458"],"award-info":[{"award-number":["IG13458"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"publisher","award":["PRA2014"],"award-info":[{"award-number":["PRA2014"]}],"id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IRCCS San Martino - IST (IT)","award":["5Xmille grant"],"award-info":[{"award-number":["5Xmille grant"]}]},{"name":"Fondazione Buzzi UNICEM (IT)","award":["FBU P28"],"award-info":[{"award-number":["FBU P28"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13287-017-0573-7","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T08:20:54Z","timestamp":1495700454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells"],"prefix":"10.1186","volume":"8","author":[{"given":"Alessandra","family":"Pattarozzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Carra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto E.","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"W\u00fcrth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Marubbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Angela","family":"Filiberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-996X","authenticated-orcid":false,"given":"Tullio","family":"Florio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Daga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"573_CR1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ccm.2012.12.005","volume":"34","author":"AR Haas","year":"2013","unstructured":"Haas AR, Sterman DH. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. Clin Chest Med. 2013;34:99\u2013111.","journal-title":"Clin Chest Med"},{"key":"573_CR2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tips.2011.03.011","volume":"32","author":"RE Favoni","year":"2011","unstructured":"Favoni RE, Florio T. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma. Trends Pharmacol Sci. 2011;32:463\u201379.","journal-title":"Trends Pharmacol Sci"},{"key":"573_CR3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2174\/1389450116666150804110714","volume":"17","author":"S Thellung","year":"2016","unstructured":"Thellung S, Favoni RE, Wurth R, Nizzari M, Pattarozzi A, Daga A, Florio T, Barbieri F. Molecular pharmacology of malignant pleural mesothelioma: challenges and perspectives from preclinical and clinical studies. Curr Drug Targets. 2016;17:824\u201349.","journal-title":"Curr Drug Targets"},{"key":"573_CR4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.drudis.2012.06.001","volume":"17","author":"T Florio","year":"2012","unstructured":"Florio T, Barbieri F. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Drug Discov Today. 2012;17:1103\u201310.","journal-title":"Drug Discov Today"},{"key":"573_CR5","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1111\/febs.13023","volume":"281","author":"S Colak","year":"2014","unstructured":"Colak S, Medema JP. Cancer stem cells\u2014important players in tumor therapy resistance. FEBS J. 2014;281:4779\u201391.","journal-title":"FEBS J"},{"key":"573_CR6","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","volume":"166","author":"RE Favoni","year":"2012","unstructured":"Favoni RE, Daga A, Malatesta P, Florio T. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br J Pharmacol. 2012;166:532\u201353.","journal-title":"Br J Pharmacol"},{"key":"573_CR7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-14-304","volume":"14","author":"L Cortes-Dericks","year":"2014","unstructured":"Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity. BMC Cancer. 2014;14:304.","journal-title":"BMC Cancer"},{"key":"573_CR8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/carcin\/bgr127","volume":"32","author":"C Frei","year":"2011","unstructured":"Frei C, Opitz I, Soltermann A, Fischer B, Moura U, Rehrauer H, Weder W, Stahel R, Felley-Bosco E. Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis. 2011;32:1324\u201332.","journal-title":"Carcinogenesis"},{"key":"573_CR9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2010.04.020","volume":"70","author":"K Kai","year":"2010","unstructured":"Kai K, D'Costa S, Yoon BI, Brody AR, Sills RC, Kim Y. Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer. 2010;70:146\u201351.","journal-title":"Lung Cancer"},{"key":"573_CR10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2407-10-54","volume":"10","author":"A Melotti","year":"2010","unstructured":"Melotti A, Daga A, Marubbi D, Zunino A, Mutti L, Corte G. In vitro and in vivo characterization of highly purified human mesothelioma derived cells. BMC Cancer. 2010;10:54.","journal-title":"BMC Cancer"},{"key":"573_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbrc.2012.02.054","volume":"419","author":"H Yamazaki","year":"2012","unstructured":"Yamazaki H, Naito M, Ghani FI, Dang NH, Iwata S, Morimoto C. Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells. Biochem Biophys Res Commun. 2012;419:529\u201336.","journal-title":"Biochem Biophys Res Commun"},{"key":"573_CR12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bcp.2011.07.073","volume":"82","author":"F Barbieri","year":"2011","unstructured":"Barbieri F, Wurth R, Favoni RE, Pattarozzi A, Gatti M, Ratto A, Ferrari A, Bajetto A, Florio T. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1\/2 as antitumor targets. Biochem Pharmacol. 2011;82:1467\u201377.","journal-title":"Biochem Pharmacol"},{"key":"573_CR13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000339259","volume":"83","author":"P Astoul","year":"2012","unstructured":"Astoul P, Roca E, Galateau-Salle F, Scherpereel A. Malignant pleural mesothelioma: from the bench to the bedside. Respiration. 2012;83:481\u201393.","journal-title":"Respiration"},{"key":"573_CR14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/156800910791054130","volume":"10","author":"RE Favoni","year":"2010","unstructured":"Favoni RE, Pattarozzi A, Lo Casto M, Barbieri F, Gatti M, Paleari L, Bajetto A, Porcile C, Gaudino G, Mutti L, et al. Gefitinib targets EGFR dimerization and ERK1\/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. Curr Cancer Drug Targets. 2010;10:176\u201391.","journal-title":"Curr Cancer Drug Targets"},{"key":"573_CR15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","volume":"37","author":"V Agarwal","year":"2011","unstructured":"Agarwal V, Lind MJ, Cawkwell L. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? Cancer Treat Rev. 2011;37:533\u201342.","journal-title":"Cancer Treat Rev"},{"key":"573_CR16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"573_CR17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125\u201334.","journal-title":"N Engl J Med"},{"key":"573_CR18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"573_CR19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17460441.2015.1006194","volume":"10","author":"PT White","year":"2015","unstructured":"White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin Drug Discov. 2015;10:427\u201339.","journal-title":"Expert Opin Drug Discov"},{"key":"573_CR20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4161\/cc.23372","volume":"12","author":"E Carra","year":"2013","unstructured":"Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T, Daga A. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle. 2013;12:491\u2013500.","journal-title":"Cell Cycle"},{"key":"573_CR21","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3892\/or.2015.3805","volume":"33","author":"G Chen","year":"2015","unstructured":"Chen G, Nicula D, Renko K, Derwahl M. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncol Rep. 2015;33:1994\u20132000.","journal-title":"Oncol Rep"},{"key":"573_CR22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jss.2013.05.016","volume":"185","author":"R Gedaly","year":"2013","unstructured":"Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J Surg Res. 2013;185:225\u201330.","journal-title":"J Surg Res"},{"key":"573_CR23","doi-asserted-by":"crossref","first-page":"126586","DOI":"10.1155\/2014\/126586","volume":"2014","author":"R Wurth","year":"2014","unstructured":"Wurth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int. 2014;2014:126586.","journal-title":"Biomed Res Int"},{"key":"573_CR24","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.4161\/cc.21193","volume":"11","author":"M Cervello","year":"2012","unstructured":"Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle. 2012;11:2843\u201355.","journal-title":"Cell Cycle"},{"key":"573_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1215\/15228517-2006-023","volume":"9","author":"A Bajetto","year":"2007","unstructured":"Bajetto A, Barbieri F, Pattarozzi A, Dorcaratto A, Porcile C, Ravetti JL, Zona G, Spaziante R, Schettini G, Florio T. CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro. Neuro Oncol. 2007;9:3\u201311.","journal-title":"Neuro Oncol"},{"key":"573_CR26","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1074\/jbc.M807111200","volume":"284","author":"F Griffero","year":"2009","unstructured":"Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, Pattarozzi A, Gatti M, Bajetto A, Porcile C, Barbieri F, et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem. 2009;284:7138\u201348.","journal-title":"J Biol Chem"},{"key":"573_CR27","doi-asserted-by":"crossref","first-page":"29004","DOI":"10.1074\/jbc.M403573200","volume":"279","author":"A Massa","year":"2004","unstructured":"Massa A, Barbieri F, Aiello C, Arena S, Pattarozzi A, Pirani P, Corsaro A, Iuliano R, Fusco A, Zona G, et al. The expression of the phosphotyrosine phosphatase DEP-1\/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. J Biol Chem. 2004;279:29004\u201312.","journal-title":"J Biol Chem"},{"key":"573_CR28","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.18632\/oncotarget.2617","volume":"5","author":"M Gritti","year":"2014","unstructured":"Gritti M, Wurth R, Angelini M, Barbieri F, Peretti M, Pizzi E, Pattarozzi A, Carra E, Sirito R, Daga A, et al. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget. 2014;5:11252\u201368.","journal-title":"Oncotarget"},{"key":"573_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fnmol.2016.00107","volume":"9","author":"F Angeletti","year":"2016","unstructured":"Angeletti F, Fossati G, Pattarozzi A, Wurth R, Solari A, Daga A, Masiello I, Barbieri F, Florio T, Comincini S. Inhibition of the autophagy pathway synergistically potentiates the cytotoxic activity of Givinostat (ITF2357) on human glioblastoma cancer stem cells. Front Mol Neurosci. 2016;9:107.","journal-title":"Front Mol Neurosci"},{"key":"573_CR30","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1080\/15384101.2015.1090063","volume":"14","author":"B Banelli","year":"2015","unstructured":"Banelli B, Carra E, Barbieri F, Wurth R, Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi D, et al. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle. 2015;14:3418\u201329.","journal-title":"Cell Cycle"},{"key":"573_CR31","doi-asserted-by":"crossref","first-page":"38638","DOI":"10.18632\/oncotarget.9575","volume":"7","author":"A Corsaro","year":"2016","unstructured":"Corsaro A, Bajetto A, Thellung S, Begani G, Villa V, Nizzari M, Pattarozzi A, Solari A, Gatti M, Pagano A, et al. Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells. Oncotarget. 2016;7:38638\u201357.","journal-title":"Oncotarget"},{"key":"573_CR32","first-page":"1838","volume":"15","author":"T Florio","year":"2001","unstructured":"Florio T, Arena S, Thellung S, Iuliano R, Corsaro A, Massa A, Pattarozzi A, Bajetto A, Trapasso F, Fusco A, Schettini G. The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation. Mol Endocrinol. 2001;15:1838\u201352.","journal-title":"Mol Endocrinol"},{"key":"573_CR33","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.humpath.2005.08.008","volume":"36","author":"NG Ordonez","year":"2005","unstructured":"Ordonez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol. 2005;36:1163\u20137.","journal-title":"Hum Pathol"},{"key":"573_CR34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.pap.0000213007.48479.94","volume":"13","author":"NG Ordonez","year":"2006","unstructured":"Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13:16\u201325.","journal-title":"Adv Anat Pathol"},{"key":"573_CR35","first-page":"143","volume":"27","author":"A Bajetto","year":"2013","unstructured":"Bajetto A, Porcile C, Pattarozzi A, Scotti L, Aceto A, Daga A, Barbieri F, Florio T. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility. J Biol Regul Homeost Agents. 2013;27:143\u201354.","journal-title":"J Biol Regul Homeost Agents"},{"key":"573_CR36","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","volume":"12","author":"LA Marek","year":"2014","unstructured":"Marek LA, Hinz TK, von Massenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, et al. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res. 2014;12:1460\u20139.","journal-title":"Mol Cancer Res"},{"key":"573_CR37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.bbamcr.2012.01.004","volume":"1823","author":"I Ahmad","year":"2012","unstructured":"Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 2012;1823:850\u201360.","journal-title":"Biochim Biophys Acta"},{"key":"573_CR38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/138161213804581963","volume":"19","author":"SB Kumar","year":"2013","unstructured":"Kumar SB, Narasu L, Gundla R, Dayam R, J ARPS. Fibroblast growth factor receptor inhibitors. Curr Pharm Des. 2013;19:687\u2013701.","journal-title":"Curr Pharm Des"},{"key":"573_CR39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","volume":"9","author":"J Lee","year":"2006","unstructured":"Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391\u2013403.","journal-title":"Cancer Cell"},{"key":"573_CR40","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2217\/fon.15.85","volume":"11","author":"G Gadaleta-Caldarola","year":"2015","unstructured":"Gadaleta-Caldarola G, Infusino S, Divella R, Ferraro E, Mazzocca A, De Rose F, Filippelli G, Abbate I, Brandi M. Sorafenib: 10 years after the first pivotal trial. Future Oncol. 2015;11:1863\u201380.","journal-title":"Future Oncol"},{"key":"573_CR41","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/annonc\/mdl017","volume":"17","author":"H Richly","year":"2006","unstructured":"Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol. 2006;17:866\u201373.","journal-title":"Ann Oncol"},{"key":"573_CR42","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","volume":"5","author":"S Dubey","year":"2010","unstructured":"Dubey S, Janne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010;5:1655\u201361.","journal-title":"J Thorac Oncol"},{"key":"573_CR43","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","volume":"8","author":"S Papa","year":"2013","unstructured":"Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, Cane P, Lang-Lazdunski L, Viney Z, Dunn JT, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013;8:783\u20137.","journal-title":"J Thorac Oncol"},{"key":"573_CR44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-015-1297-7","volume":"15","author":"T Yamada","year":"2015","unstructured":"Yamada T, Abei M, Danjoh I, Shirota R, Yamashita T, Hyodo I, Nakamura Y. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. BMC Cancer. 2015;15:260.","journal-title":"BMC Cancer"},{"key":"573_CR45","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2011.400","volume":"105","author":"E Giovannetti","year":"2011","unstructured":"Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, et al. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer. 2011;105:1542\u201353.","journal-title":"Br J Cancer"},{"key":"573_CR46","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129\u201340.","journal-title":"Mol Cancer Ther"},{"key":"573_CR47","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426\u201337.","journal-title":"Oncologist"},{"key":"573_CR48","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"573_CR49","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1158\/0008-5472.CAN-09-1076","volume":"69","author":"K Takezawa","year":"2009","unstructured":"Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 2009;69:6515\u201321.","journal-title":"Cancer Res"},{"key":"573_CR50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-015-1186-0","volume":"15","author":"M Broecker-Preuss","year":"2015","unstructured":"Broecker-Preuss M, Muller S, Britten M, Worm K, Kurt Werner S, Mann K, Fuhrer D. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer. 2015;15:184.","journal-title":"BMC Cancer"},{"key":"573_CR51","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12885-015-1363-1","volume":"15","author":"Y Pignochino","year":"2015","unstructured":"Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basirico M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, et al. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer. 2015;15:374.","journal-title":"BMC Cancer"},{"key":"573_CR52","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/erm.2012.6","volume":"14","author":"PA Rascoe","year":"2012","unstructured":"Rascoe PA, Jupiter D, Cao X, Littlejohn JE, Smythe WR. Molecular pathogenesis of malignant mesothelioma. Expert Rev Mol Med. 2012;14:e12.","journal-title":"Expert Rev Mol Med"},{"key":"573_CR53","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/onc.2014.314","volume":"34","author":"P Ramos","year":"2015","unstructured":"Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2015;34:3617\u201326.","journal-title":"Oncogene"},{"key":"573_CR54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","volume":"190","author":"K Schelch","year":"2014","unstructured":"Schelch K, Hoda MA, Klikovits T, Munzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, et al. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. Am J Respir Crit Care Med. 2014;190:763\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"573_CR55","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2174\/1871520616666160204112347","volume":"16","author":"F Biello","year":"2016","unstructured":"Biello F, Burrafato G, Rijavec E, Genova C, Barletta G, Truini A, Coco S, Dal Bello MG, Alama A, Boccardo F, Grossi F. Fibroblast growth factor receptor (FGFR): a new target for non-small cell lung cancer therapy. Anticancer Agents Med Chem. 2016;16:1142\u201354.","journal-title":"Anticancer Agents Med Chem"},{"key":"573_CR56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"573_CR57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/mol.108.049544","volume":"75","author":"L Marek","year":"2009","unstructured":"Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009;75:196\u2013207.","journal-title":"Mol Pharmacol"},{"key":"573_CR58","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-10-2727","volume":"17","author":"R Sharpe","year":"2011","unstructured":"Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A, Turner NC. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011;17:5275\u201386.","journal-title":"Clin Cancer Res"},{"key":"573_CR59","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/1078-0432.CCR-11-0050","volume":"17","author":"ME Marshall","year":"2011","unstructured":"Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011;17:5016\u201325.","journal-title":"Clin Cancer Res"},{"key":"573_CR60","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1541-7786.MCR-12-0652","volume":"11","author":"H Terai","year":"2013","unstructured":"Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013;11:759\u201367.","journal-title":"Mol Cancer Res"},{"key":"573_CR61","doi-asserted-by":"crossref","first-page":"39861","DOI":"10.18632\/oncotarget.9515","volume":"7","author":"C Blackwell","year":"2016","unstructured":"Blackwell C, Sherk C, Fricko M, Ganji G, Barnette M, Hoang B, Tunstead J, Skedzielewski T, Alsaid H, Jucker BM, et al. Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230. Oncotarget. 2016;7:39861\u201371.","journal-title":"Oncotarget"},{"key":"573_CR62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","volume":"437","author":"J Wesche","year":"2011","unstructured":"Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011;437:199\u2013213.","journal-title":"Biochem J"},{"key":"573_CR63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tox.2013.10.003","volume":"314","author":"M Gatti","year":"2013","unstructured":"Gatti M, Pattarozzi A, Bajetto A, Wurth R, Daga A, Fiaschi P, Zona G, Florio T, Barbieri F. Inhibition of CXCL12\/CXCR4 autocrine\/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology. 2013;314:209\u201320.","journal-title":"Toxicology"},{"key":"573_CR64","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","volume":"3","author":"MV Dieci","year":"2013","unstructured":"Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3:264\u201379.","journal-title":"Cancer Discov"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-017-0573-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T21:54:29Z","timestamp":1569362069000},"score":1,"resource":{"primary":{"URL":"http:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-017-0573-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1186\/s13287-017-0573-7","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]},"article-number":"119"}}